Allergen Immunotherapy Compliance and Patient Outcomes

Allergen immunotherapy (AIT) represents the only disease-modifying treatment for IgE-mediated respiratory allergies, offering long-term symptomatic relief by inducing immunological tolerance. Effective outcomes depend critically on patient adherence, which may be challenged by treatment duration, route of administration and adverse events. Subcutaneous immunotherapy (SCIT) typically requires clinic visits over several years, while sublingual immunotherapy (SLIT) can be self-administered at home but may suffer from inconsistent dose intake. Poor compliance not only undermines clinical benefit but also reduces quality of life and inflates healthcare costs through wasted doses and repeated symptom management. Conversely, high adherence correlates with sustained reduction in symptom scores, decreased medication use and improved health-related quality of life. Recent work has explored predictive models for non-adherence, protocol modifications to simplify build-up schedules, and support programmes to engage patients. Global studies highlight substantial variations in persistence across regions and age groups, underlining the need for tailored interventions. Beyond efficacy, the ecological impact of immunotherapy—particularly patient travel to clinics—has also emerged as a factor in treatment choice. Overall, optimisation of adherence through technological, educational and logistical strategies is central to maximising the clinical and societal benefits of AIT worldwide.

Research from Nature Portfolio

Recent studies have quantified the environmental and logistical advantages of SLIT over SCIT. In a national Swedish analysis, models combining clinic-location data and transport patterns estimated that switching all patients from SCIT injections to SLIT tablets could cut annual travel-related CO2 emissions by approximately 1,300 tonnes and reduce patient travel time by over 210,000 hours. These findings underscore how route selection influences not only individual adherence through convenience but also broader sustainability goals, suggesting that environmental metrics can inform shared decision-making in AIT.

Allergen Immunotherapy Compliance and Patient Outcomes publication trend

The graph below shows the total number of articles in allergen immunotherapy compliance and patient outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Allergen immunotherapy (AIT): A treatment that aims to induce long-term tolerance to specific allergens through repeated controlled exposure.
Subcutaneous immunotherapy (SCIT): AIT delivered by regular injections of allergen extract, typically in a clinical setting.
Sublingual immunotherapy (SLIT): AIT administered as allergen drops or tablets under the tongue, usually self-administered at home.
Adherence (compliance): The degree to which a patient follows the prescribed treatment schedule and dosing.
Long short-term memory (LSTM) network: A type of recurrent neural network capable of learning time-series patterns for forecasting outcomes such as treatment adherence.

References

1. Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence. Allergy, Asthma & Clinical Immunology (2016).
2. Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO2 emissions in Sweden. Scientific Reports (2024).
3. Sequential model for predicting patient adherence in subcutaneous immunotherapy for allergic rhinitis. Frontiers in Pharmacology (2024).
4. Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build‐Up Phase: A Retrospective Study. BioMed Research International (2020).
5. Adherence and quality of life in adults and children during 3-years of SLIT treatment with Grazax—a real life study. npj Primary Care Respiratory Medicine (2018).